Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bleeding Risk For Endologix AAA Grafts Reconfirmed

Patients with the grafts should undergo imaging scans each year, US FDA says

Executive Summary

Postmarket monitoring continues to show a consistent risk of type III endoleaks in patients with Endologix AFX grafts.

You may also be interested in...



Bleeding Risks Still A Concern For Patients With Endologix Stent Grafts: FDA Advisory Panel

The US agency’s Circulatory System Devices Panel found type III endoleaks are still a problem for abdominal aortic aneurysm patients treated with the newest Endologix stent graft, though for some the benefits still outweigh the risks. The panel advised that all patients, however, should continue getting annual screenings.

Leak Risk Tied To Endologix Grafts Found In More Models, FDA Says

A recent warning from the US agency ties two additional models of AFX endovascular grafts from Endologix Inc. to potentially fatal blood leaks. An earlier model of the devices, which are used to treat abdominal aortic aneurysms, was removed from the market last year over similar concerns.

Discontinued Endologix AAA Graft Device Singled Out In Updated FDA Alert

US FDA says that previously identified elevated risks of type III endoleaks from endovascular aneurysm repair systems appears to be linked to a specific, no-longer-sold device, Endogix's AFX with Strata system.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT143176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel